Related Experiment Video
Updated: Aug 1, 2025
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Beta-Blockers in the Prevention and Treatment of Ischemic Heart Disease: Evidence and Clinical Practice
Omer Khan1, Murti Patel1,2, Anna N Tomdio1,2
1Department of Medicine, Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, USA.
Insights
Beta-blockers are crucial for acute myocardial infarction but offer less benefit over time. Their effectiveness in perioperative settings for coronary artery disease is not strongly supported by current evidence.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary artery disease (CAD) involves plaque buildup, obstructing blood flow.
- Treatment includes lifestyle changes, medication, and revascularization.
- Beta-adrenoceptor antagonists (beta-blockers) are a cornerstone therapy for CAD.
Purpose of the Study:
- To review evidence on beta-blocker use in acute coronary syndrome, stable CAD, and perioperative settings.
- To evaluate the efficacy of beta-blockers based on the timing of cardiac events.
- To assess the role of beta-blockers in perioperative cardiovascular care.
Main Methods:
- Systematic review of prior studies.
- Analysis of clinical trial data.
- Examination of evidence for different patient populations and settings.
Main Results:
- Beta-blocker therapy is well-established for acute myocardial infarction.
- Evidence for beta-blocker benefit diminishes with time post-myocardial infarction.
- The evidence supporting beta-blocker use in the perioperative setting is not robust.
Conclusions:
- Beta-blockers remain vital in acute settings for CAD management.
- Long-term and perioperative benefits require further investigation.
- Clinical decisions regarding beta-blocker use should consider the specific patient context and timing of events.
Abstract:
Coronary artery disease (CAD) is the most prevalent cardiovascular disease characterized by atherosclerotic plaque buildup that can lead to partial or full obstruction of blood flow in the coronary arteries. Treatment for CAD involves a combination of lifestyle changes, pharmacologic therapy, and modern revascularization procedures. Beta-adrenoceptor antagonists (or beta-blockers) have been widely used for decades as a key therapy for CAD. In this review, prior studies are examined to better understand beta-adrenoceptor antagonist use in patients with acute coronary syndrome, stable coronary heart disease, and in the perioperative setting. The evidence for the benefit of beta-blocker therapy is well established for patients with acute myocardial infarction, but it diminishes as the time from the index cardiac event elapses. The evidence for benefit in the perioperative setting is not strong.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:28Antihypertensive Drugs: Types of β-Blockers
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....